News

Primary end point data from the phase 2 KEYNOTE-695 study did not meet the prespecified end point of overall response rate for patients with advanced melanoma.

Bruno Bockorny, MD, explains the mechanism of action of botensilimab and its use in combination with balstilimab for ovarian cancer treatment.

The FDA continues to push forward PSMA-targeted therapies to address unmet needs for patients with metastatic castration-resistant prostate cancer.

Promising results from a type C meeting with the FDA has led to a phase 2/3 trial of darovasertib and crizotinib being initiated in 2023 for patients with first-line HLA-A2 negative metastatic uveal melanoma.

Significant rates of homologous recombination deficiency somatic gene mutations were found in patients with uterine serous cancer, resulting in possible implications for future testing and treatment for the patient population, according to the results of a research study.

Promising efficacy has been seen with the use of immunotherapy for the management of patients with hepatocellular carcinoma, Now, durvalumab and tremelimumab combination therapy is being studied for this patient population listed for a liver transplant.

A phase 1 trial of EPI-7386 will evaluate the safety, pharmacokinetics, drug-drug interactions, and preliminary anti-tumor activity of the agent in combination with apalutamide or abiraterone acetate plus prednisone.

Many questions remain unanswered about COVID-19, and we are now experiencing another problem—postacute sequelae of SARS-CoV-2 infection, also referred to as post–COVID-19 condition or post-COVID syndrome.

Pierre Gholam, MD, discusses the phase 3 LEAP-002 study of lenvatinib and pembrolizumab for unresectable hepatocellular carcinoma.

Investigators of the phase 2 KRYSTAL-1 have reported important findings that may be practice-changing for oncologists who treat various KRAS G12C-mutant solid tumors, in the future.

An analysis of 4 deidentified data sets revealed that HRAS mutations occurred in 3% to 4% of patients with head and neck squamous cell carcinoma.

Researchers are backing further investigation of 60 mg selinexor plus ruxolitinib based on positive phase 1/2 findings presented at the AACR Annual Meeting 2023.

The new Prescription Drug User Fee Act action date for quizartinib for use in patients with newly diagnosed FLT3-ITD-positive acute myeloid leukemia has been set to July 24, 2023.

Findings presented at the ASCO April Plenary Series showed that there was a significant event-free survival improvement among patients treated with toripalimab in the phase 3 Neotorch study.

Chad Tang, MD, discusses currently available treatment options and recent research in the prostate cancer space.

The phase 3 CheckMate 914 study has missed its primary end point, and the lack of efficacy of nivolumab plus ipilimumab over placebo in the study has led investigators to refer oncologists back to the standard of care, pembrolizumab, as seen in KEYNOTE-564.

Researchers are working to optimize the outcomes associated with CAR T-cell therapy, focusing on unique combinations that may enhance T-cell fitness, improving tumor eradication and treatment outcomes.

In an interview, Samer A. Srour, MD, MS, reviewed data from the dose-expansion phase of an ongoing phase 1 trial of Orca-Q in the haploidentical stem cell transplant setting for patients with high-risk hematologic malignancies.

In an interview with Targeted Oncology, Mitchell E. Horwitz, MD, discussed the FDA approval of omidubicel for the treatment of patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant.

On the heels of a positive ODAC vote, polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone is now FDA-approved.

Complete remission was achieved in 99% patients with refractory leukemia or hematologic relapse when treated with CD19- and CD22-chimeric antigen receptor T-cell therapy in a phase 2 trial.

DKN-01, an anti-DKK1 antibody, is being evaluated with bevacizumab and chemotherapy for patients with advanced colorectal cancer in the phase 2 DeFianCe trial.

Melanie Goldfarb, MD, MSc, FACS, FACE, discusses the current treatment landscape for patients with thyroid cancer.

At the 2023 National Comprehensive Cancer Network Annual Conference, Arlene O. Siefker-Radtke, MD, gave an assessment on where emerging targeted therapies for patients with metastatic or advanced bladder stand.

News results from. the phase 3 AEGEAN trial further support the use of PD-1/PD-L1 inhibitors in the neoadjuvant and adjuvant setting for patients with non–small cell lung cancer.

Whole-exome sequencing demonstrated the ability to identify genetic conditions in patients for whom clinical guidelines did not require testing.

In an interview, Ashish Saxena, MD, discussed the benefit of radiation for the treatment of small cell lung cancer, combining radiation with immune checkpoint blockade treatments, and the next steps for the space.

Neeta Somaiah, MD, discusses the expanding role of targeted therapies in patients with gastrointestinal stromal tumor and how these treatments are bolstering later lines of therapy.

A trial of TOS-358, a first-in-class covalent PI3Kα inhibitor, for various solid tumors dosed its first patient.

An artificial intelligence model has been shown to predict the risk of low and high distant recurrence in patients with endometrial cancer.